Article history: The goal of this study was to develop novel embolic nanoparticles for targeted tumor therapy with dual Received 4 November 2011 targeting: magnetic ﬁeld-guided and peptide-directed targeting. The embolic nanoparticles SP5.2/tTF- Received in revised form 14 January 2012 OCMCs-SPIO-NPs were prepared by surface-modifying of superparamagnetic iron oxide nanoparticles Accepted 19 January 2012 (SPIO-NPs) with o-carboxymethylchitosans (OCMCs) and SP5.2/tTF (SP5.2: a peptide binding to VEGFR- Available online 30 January 2012 1; tTF: truncated tissue factor) to improve their stability and to target over-expressing VEGFR-1 cells. The physicochemical characterization results showed that the OCMCs-SPIO-NPs have a spherical or Keywords: ellipsoidal morphology with an average diameter of 10–20 nm. And they possess magnetism with a Magnetic nanoparticles saturation magnetization of 66.1 emu/g, negligible coercivity and remanence at room temperature. In Superparamagnetic addition, the confocal microscopy, Prussian blue staining and FX activation analysis respectively demon- o-Carboxymethylchitosan strated the peptide-directed targeting, magnetic ﬁeld-guided targeted and blood coagulation activity of Truncated tissue factor Tumor targeting the SP5.2/tTF-OCMCs-SPIO-NPs. These properties separately belong to SP5.2, Fe O and tTF moieties of 3 4 the SP5.2/tTF-OCMCs-SPIO-NPs. Thus these SP5.2/tTF-OCMCs-SPIO-NPs with double-targeting function should have a potential application in embolization therapy of tumor blood vessels. © 2012
International Journal of Pharmaceutics – Elsevier
Published: Apr 15, 2012
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
All the latest content is available, no embargo periods.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud